Investing.com -- Recursion Pharmaceuticals Inc (NASDAQ: RXRX) stock surged 11.5% while Rallybio Corp (NASDAQ: RLYB) shares ...

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced ...

Rallybio has agreed to sell its interest in a drug-development plan seeking to treat a rare genetic bone disease to its joint-venture partner Recursion Pharmaceuticals for up to $25 million.

The REV102 program originated from a joint venture between Rallybio and Recursion focused on the discovery and development of novel, orally available small molecule inhibitors of ENPP1 for the ...

In addition, Rallybio may be eligible to receive certain payments in the event of Recursion’s sale of the REV102 program.

Rallybio has swerved away from its Recursion Pharmaceuticals pact, accepting $7.5 million upfront for its share of a preclinical program to extend its cash runway to mid-2027.

Shares in biotech company Recursion Pharmaceuticals ( RXRX 12.07%) surged by more than 12% by 11 a.m. ET today. The move is ...

Under the agreement, Rallybio will also receive low single-digit royalties on future net sales and may be eligible for additional payments if Recursion sells the program.

SAN ANTONIO, TX, UNITED STATES, July 10, 2025 /EINPresswire.com/ -- Independent AI researcher Mark McLemore today published groundbreaking findings demonstrating that core AGI behaviors are already ...

Some people slander retrocomputing as an old man’s game, just because most of those involved are more ancient than the hardware they’re playing with. But there are veritable children ...